TGTX Reports Positive Topline Results from ENHANCE Trial, Meets Primary Endpoint for BRIUMVI Single Infusion Regimen, Targets sBLA Filing in 2H-2026
TG Therapeutics, Inc. · PHARMACEUTICAL PREPARATIONS · Now $37.94
-1.0% in 1d after detection
Post-detection moves
1h
0.0%
1d
-1.0%
3d
—
7d
—
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS